Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1191)	4/23/1998 4:12:00 PM
From: Grainne	Read Replies (1) \| Respond to of 1359

The information that you provided is really helpful to me, Neuro. It seems very unfair, in a way, that the results reflect trial design failure, not drug failure, and that the results of the studies involving 800 patients are no longer significant because of the failure of this smaller one, but the stock market is not a fair place, and biotech is full of stories like this one. Do you have any idea of the time frame before we would have results of the new, 700 patient study that Interneuron is laying the groundwork for? Sounds like a long time!! This is all very discouraging, in a way, because Interneuron itself is partially responsible. It makes waiting for drugs in the pipeline look like a pretty rocky ride. Thanks so much!!